Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of zongertinib in HER2-mutant non-small cell lung cancer with poor performance status
jRCT1061260039Phase 2Recruiting
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zongertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Objective response rate. Started Jul 2026; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1061260039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260039.